Perrigo Makes Its Rx Generics Business Look Right At Home
Executive Summary
Board bloc still is pushing to divest the Rx segment, though it achieved 4% volume sales growth and $6m in new product sales in the second quarter. Apparent second-quarter validation isn't enough to persuade CEO John Hendrickson to stay on.
You may also be interested in...
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.
Perrigo's Next Private Label First Lands With Second Thoughts On Outlook
The launch of a private label version 24HR OTC heartburn treatment comes with Perrigo in need of another high-selling product to boost revenues in its core business, OTC private label. But analysts call for Perrigo to do more to grow in new markets.